Murakami Keishu, Koh Jinsoo, Ogami Shuhei, Aoki Yohei, Hori Kohei, Emori Seiji, Matsumoto Takuya, Taruya Junko, Yorozu Shoko, Sakata Mayumi, Nakayama Yoshiaki, Miyamoto Katsuichi, Ito Hidefumi
Department of Neurology, Wakayama Medical University, Wakayama, JPN.
Department of Neurology, National Hospital Organization Wakayama Hospital, Wakayama, JPN.
Cureus. 2024 Jul 24;16(7):e65316. doi: 10.7759/cureus.65316. eCollection 2024 Jul.
Sarcopenia is a skeletal muscle disease manifesting as low muscle mass and impaired muscle function. It has been reported that sarcopenia correlates with a low quality of life (QOL) and an increased risk of falls in patients with Parkinson's disease (PD). Nevertheless, few studies have investigated the prevalence, impact, and screening methods of sarcopenia in Japanese patients with PD.
Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia 2019 consensus. We compared demographic characteristics, severity of PD, levodopa equivalent daily dose, QOL, fatigue, impulsive and compulsive behaviors, body mass index (BMI), calf circumference, skeletal muscle mass index (SMI), handgrip strength, a 4-meter gait speed, a five-time sit-to-stand test (FTSST), short physical performance battery, and SARC-F questionnaire scores between sarcopenia and non-sarcopenia groups. Furthermore, to investigate the best tool for screening sarcopenia in PD, the sensitivity and specificity of calf circumference, handgrip strength, FTSST, and SARC-F questionnaire were compared.
The prevalence of sarcopenia in PD was 31.9% (15/47). The sarcopenia group showed significantly higher age (77.3 ± 5.12 versus 70.3 ± 8.17, p = 0.0042), lower BMI (19.3 ± 2.99 versus 23.3 ± 3.18, p = 0.0002), higher rate of decreased calf circumference (86.6% versus 34.3%, p = 0.0013) and SMI (100% versus 6.25%, p < 0.0001), and worse FTSST (15.5 ± 5.57 versus 12.0 ± 4.12, p = 0.0219). The other parameters were not significantly different. Among screening tools, calf circumference had the highest sensitivity (86%) and specificity (65%). All screening tools had higher sensitivity and specificity in men than in women. The SARC-F questionnaire was not useful in distinguishing sarcopenia but was significantly correlated with the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part 3 (r = 0.41, p = 0.0037) and the 39-item Parkinson's Disease QOL Scale (r = 0.71, p < 0.0001).
This study investigated the characteristics of PD patients with sarcopenia in Japan. Calf circumference was found to be the most useful tool for screening sarcopenia in PD. Handgrip strength and FTSST also showed high sensitivities, particularly in men. Conversely, the SARC-F questionnaire is not suitable for diagnosing sarcopenia in PD.
肌肉减少症是一种骨骼肌疾病,表现为肌肉量减少和肌肉功能受损。据报道,肌肉减少症与帕金森病(PD)患者的生活质量(QOL)低下和跌倒风险增加相关。然而,很少有研究调查日本PD患者中肌肉减少症的患病率、影响及筛查方法。
根据2019年亚洲肌肉减少症工作组共识诊断肌肉减少症。我们比较了肌肉减少症组和非肌肉减少症组之间的人口统计学特征、PD严重程度、左旋多巴等效日剂量、QOL、疲劳、冲动和强迫行为、体重指数(BMI)、小腿围、骨骼肌质量指数(SMI)、握力、4米步速、五次坐立试验(FTSST)、简易体能状况量表以及SARC-F问卷得分。此外,为了研究筛查PD患者肌肉减少症的最佳工具,比较了小腿围、握力、FTSST和SARC-F问卷的敏感性和特异性。
PD患者中肌肉减少症的患病率为31.9%(15/47)。肌肉减少症组的年龄显著更高(77.3±5.12对70.3±8.17,p = 0.0042),BMI更低(19.3±2.99对23.3±3.18,p = 0.0002),小腿围减小率更高(86.6%对34.3%,p = 0.0013)和SMI更高(100%对6.25%,p < 0.0001),FTSST更差(15.5±5.57对12.0±4.12,p = 0.0219)。其他参数无显著差异。在筛查工具中,小腿围的敏感性最高(86%)和特异性最高(65%)。所有筛查工具在男性中的敏感性和特异性均高于女性。SARC-F问卷在区分肌肉减少症方面无用,但与运动障碍协会赞助修订的统一帕金森病评定量表第3部分显著相关(r = 0.41,p = 0.0037)和39项帕金森病QOL量表(r = 0.71,p < 0.0001)。
本研究调查了日本PD合并肌肉减少症患者的特征。发现小腿围是筛查PD患者肌肉减少症最有用的工具。握力和FTSST也显示出高敏感性,尤其是在男性中。相反,SARC-F问卷不适用于诊断PD患者的肌肉减少症。